This finding extends the cardiovascular benefit profile beyond GLP-1 agents already approved for cardiometabolic risk reduction, providing family physicians with additional evidence to support GLP-1 therapy in patients with obesity and established cardiovascular disease or multiple risk factors. The oral formulation data is clinically relevant as it may improve patient adherence compared to injectable alternatives, potentially increasing the proportion of eligible patients who can sustain treatment and achieve durable cardiovascular and metabolic benefits. For primary care practices, this expands the clinical rationale for GLP-1 initiation beyond weight loss and glycemic control to include explicit cardiovascular risk mitigation in appropriate candidates.
Eli Lilly’s Foundayo (retatrutide), an oral formulation of the GLP-1 receptor and glucose-dependent insulinotropic polypeptide receptor dual agonist, demonstrated cardiovascular benefits in late-stage clinical trial data. The study evaluated the drug’s effects on major adverse cardiovascular events in patients with obesity or overweight with established cardiovascular disease. Results showed clinically meaningful reductions in the composite endpoint of myocardial infarction, stroke, and cardiovascular death, establishing that the oral GLP-1/GIP dual agonist class provides cardiovascular protection comparable to previously demonstrated benefits with injectable semaglutide formulations.
These findings extend the emerging evidence base supporting cardiovascular risk reduction with GLP-1 receptor agonists and combination GLP-1/GIP agonists in cardiometabolic disease. The data are particularly relevant given that Foundayo entered the market following the success of Wegovy as an injectable semaglutide formulation initiated in January of that year. The cardiovascular outcome data support the use of oral retatrutide in patients with obesity who carry concurrent cardiovascular risk, positioning the agent as an option for physicians managing patients where both weight reduction and cardiovascular event prevention are clinical priorities.
The availability of an oral formulation with demonstrated cardiovascular benefits addresses a significant gap in the pharmacologic management of obesity complicated by cardiovascular disease. For prescribers, these results inform treatment selection in patients with established atherosclerotic cardiovascular disease who require both metabolic and cardiovascular risk management. The data support consideration of retatrutide in this population as part of comprehensive cardiometabolic therapy.
GLP-1 receptor agonists like Wegovy have demonstrated cardiovascular benefits beyond weight loss in clinical trials. These medications reduce the risk of major adverse cardiovascular events, including heart attack and stroke, in patients with obesity and related metabolic conditions. Family physicians can use this evidence when counseling patients about the broader health benefits of GLP-1 therapy beyond weight reduction alone. When initiating GLP-1 treatment, explicitly discuss cardiovascular risk reduction as a primary health outcome to improve patient motivation and adherence, particularly in patients with established cardiovascular disease or multiple risk factors.
“This Foundayo data represents an important inflection point for the GLP-1 class because we’re now seeing cardiovascular risk reduction with an oral formulation, which mirrors what we observed with semaglutide in SUSTAIN-6 and tirzepatide in SURPASS. What matters clinically is that patients often prefer oral medications to injectables due to adherence concerns, so if Foundayo delivers comparable cardiometabolic benefits, we gain a meaningful tool for the subset of patients who will simply refuse weekly injections. In my practice, I’m already counseling patients that the mechanism of weight loss and improved metabolic parameters with GLP-1 agonists appears to confer genuine cardiovascular protection independent of weight reduction alone, and this trial strengthens that message considerably.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- What is Foundayo and how is it different from Wegovy?
- Did the study show that GLP-1 pills prevent heart attacks and strokes?
- Can GLP-1 medications like Foundayo be used for diabetes?
- Is Foundayo available right now?
- Why would I choose a GLP-1 pill over an injection?
- Are GLP-1 medications safe for long-term use?
- What happens to weight loss results if I stop taking GLP-1 medication?
- Can GLP-1 medications prevent obesity complications like heart disease?
- Who should not take GLP-1 medications?
- Will insurance cover GLP-1 medications like Foundayo?
FAQ
What is Foundayo and how is it different from Wegovy?
Foundayo is Eli Lilly’s oral GLP-1 medication, meaning you take it as a pill rather than an injection like Wegovy. Both medications work similarly in your body to help with weight loss and blood sugar control, but the pill form may be easier for some patients to use consistently.
Did the study show that GLP-1 pills prevent heart attacks and strokes?
The late-stage study showed that Foundayo lowered the risk of heart attack and stroke in patients studied. This suggests GLP-1 medications may have heart protection benefits beyond just weight loss and diabetes management.
Can GLP-1 medications like Foundayo be used for diabetes?
Yes, GLP-1 medications are approved and effective for treating type 2 diabetes. The study data supports their use in diabetes, and many patients use these medications for both blood sugar control and weight management.
Is Foundayo available right now?
Foundayo is still in late-stage clinical trials and has not yet received FDA approval for patient use. Once approved, it may become available through pharmacies, but the exact timeline depends on FDA review.
Why would I choose a GLP-1 pill over an injection?
A pill form may be more convenient for daily use since you would not need to give yourself injections. Some patients find pills easier to remember and simpler to incorporate into their daily routine.
Are GLP-1 medications safe for long-term use?
GLP-1 medications that are already approved have good safety profiles when used as prescribed under medical supervision. Your doctor will monitor you regularly to ensure the medication is working well and not causing problems.
What happens to weight loss results if I stop taking GLP-1 medication?
If you stop taking GLP-1 medication, weight loss results are typically not maintained long-term, and weight often returns over time. This is why these medications are considered ongoing treatments rather than one-time solutions.
Can GLP-1 medications prevent obesity complications like heart disease?
The study results suggest that GLP-1 medications may reduce serious heart and stroke events, which are major complications of obesity. This indicates these medications may offer protection beyond just the weight loss itself.
Who should not take GLP-1 medications?
People with a personal or family history of medullary thyroid cancer or MEN2 syndrome should not use GLP-1 medications. You should discuss your full medical history with your doctor to determine if these medications are safe for you.
Will insurance cover GLP-1 medications like Foundayo?
Insurance coverage for GLP-1 medications varies by plan and indication, with some plans covering them for diabetes and others for weight loss. You will need to check with your specific insurance company about coverage once Foundayo becomes available.
